⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7710736 | 0.80 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL7710808 | 0.80 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL3404082 | 0.80 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL11501898 | 0.80 | — | — | |
| SCHEMBL7710694 | 0.75 | SIGMAR1 (0.38) | — | |
| SCHEMBL7708108 | 0.75 | SIGMAR1 (0.38) | — | |
| SCHEMBL5694548 | 0.75 | SIGMAR1 (0.38) | — | |
| SCHEMBL1134897 | 0.75 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL1134920 | 0.75 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL25328825 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192623-A1 | Indazole Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2023-06-22 | — | — | US | claimed |
| CN-115397812-A | Indazole derivatives | 豪夫迈·罗氏有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-111072571-B | Dithiocarbamates as FAK inhibitors | 北京西博医药研究有限公司 | 2021-05-14 | — | — | CN | claimed |
| CN-111072571-A | Dithiocarbamates as FAK inhibitors | 北京西博医药研究有限公司 | 2020-04-28 | — | — | CN | claimed |
| US-10624897-B2 | Chlorobenzene substituted azaaryl compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-04-21 | — | — | US | claimed |
| US-20190083499-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2019-03-21 | — | — | US | claimed |
| EP-3324970-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | Taipei Medical University (TW) | 2018-05-30 | — | — | EP | claimed |
| WO-2017015400-A1 | CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2017-01-26 | — | — | WO | claimed |
| EP-2986610-A2 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2016-02-24 | — | — | EP | claimed |
| WO-2014172644-A2 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2014-10-23 | — | — | WO | claimed |
| EP-1569908-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2005016894-A1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2005-02-24 | — | — | WO | claimed |
| EP-1465870-A2 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINIUM SALTS, METHOD FOR PRODUCTION AND USE THEREOF AS A MEDICAMENT AND MEDICAMENTS COMPRISING THE SAME | Aventis Pharma Deutschland GmbH (DE) | 2004-10-13 | — | — | EP | claimed |
| EP-1453810-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | Aventis Pharma Deutschland GmbH (DE) | 2004-09-08 | — | — | EP | claimed |
| US-20040152902-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-08-05 | — | — | US | claimed |
| WO-2004046113-A2 | PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-06-03 | — | — | WO | claimed |
| US-6689777-B2 | DEPOLYMERIZING HEMOZOIN USING 2-IMINO-NAPHTHO(1,2-D)THIAZOL-5-OL DERIVATIVES | KENNETH S. WARREN INSTITUTE | 2004-02-10 | — | — | US | claimed |
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | KENNETH S. WARREN INSTITUTE | 2003-10-02 | — | — | US | claimed |
| WO-2003055880-A2 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINIUM SALTS, METHOD FOR PRODUCTION AND USE THEREOF AS A MEDICAMENT AND MEDICAMENTS COMPRISING THE SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-10 | — | — | WO | claimed |
| WO-2003048129-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE THEREOF AS MEDICAMENTS, IN ADDITION TO A MEDICAMENT CONTAINING SAME | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-06-12 | — | — | WO | claimed |